Loading...
Market
Total payments by Novartis to Monte Rosa by end of 2025?
2
Resolution / Starting Odds
Up to $150 million • 25%
$150 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Monte Rosa Therapeutics or Novartis financial reports
Story
Monte Rosa Therapeutics Announces $150M Global License Agreement with Novartis
Oct 28, 2024, 10:30 AM
Monte Rosa Therapeutics ($GLUE) has announced a global license agreement with Novartis ($NVS) to advance T and B Cell-modulating VAV1-directed molecular glue degraders. The deal includes $150 million upfront and potential payments up to $2.1 billion. This agreement aims to enhance Monte Rosa's capabilities in the field of targeted protein degradation, competing with companies like Kymera Therapeutics.
View original story
Similar markets
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Full $1.5 billion • 25%
$1.25 - $1.5 billion • 25%
$1 - $1.25 billion • 25%
Below $1 billion • 25%
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%